Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.

Adimmune Corp

Mr. Chi-Hsien  Chan

CEO & Chairman

Mr. Chung-Cheng  Liu

President, GM & Director

Mr. Chin-Chuan  Chang

COO and VP of R&D

Mr. Fei  Pan

Chief Legal Officer & General Counsel

Dr. Chun Cheng  Chen M.B.A., M.D., M.Sc., Ph.D.

Chief Medical Officer

Mr. Yin-Teng  Chang

Chief Financial Officer

Ms. Li-Ya  Tang

Director of Administration Center

Chih-Hsiang  Leng

Head of R&D Division

Mr. Chin-I  Chiu

Vice President of Quality Assurance Department

4142's next earnings is on June 20, 2025 (After Market Close)

4142's latest dividend is 0.5 TWD on September 14, 2021

Adimmune Corp (4142) Stock Analysis, Discussion Forum and Financial Metrics - TWSE Exchange

Adimmune Corp (4142) Earnings Report Date and History | TWSE

4142's next earnings is on June 20, 2025 (After Market Close)

When is the earnings report for 4142?

4142 Earnings History

4142's latest dividend is 0.5 TWD on September 14, 2021

4142 Stock Discussion Forum and Message Board

News for TWSE: 4142